Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones
Susana Cardoso, Paula I. Moreira
International review of neurobiology (2020), pp. 37-64
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases
Haruka Tsubaki, Ikuo Tooyama, Douglas G. Walker
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9357-9357
Open Access | Times Cited: 104
DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali K. Albuhadily, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 923-936
Closed Access | Times Cited: 22
An Update on the Potential of Tangeretin in the Management of Neuroinflammation-Mediated Neurodegenerative Disorders
Irshad Wani, Sushruta Koppula, A. C. Balda, et al.
Life (2024) Vol. 14, Iss. 4, pp. 504-504
Open Access | Times Cited: 8
Brain-specific targeted delivery of therapeutic agents using metal–organic framework-based nanomedicine
Zongsu Han, Muzhaozi Yuan, Nguyen Nguyen, et al.
Coordination Chemistry Reviews (2024) Vol. 514, pp. 215926-215926
Closed Access | Times Cited: 8
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease
Kristína Kulcsarová, Corinna Bang, Daniela Berg, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 7, pp. 1079-1106
Open Access | Times Cited: 20
Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials
Keren Esther Kristina Mantik, Sujin Kim, Bonsang Gu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11450-11450
Open Access | Times Cited: 17
Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: A retrospective cohort study
Houyu Zhao, Lin Zhuo, Yexiang Sun, et al.
Journal of Diabetes (2023) Vol. 15, Iss. 2, pp. 97-109
Open Access | Times Cited: 16
A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress
Sheng Li, Yanbing Liu, Sen Lu, et al.
Molecular and Cellular Biochemistry (2024)
Closed Access | Times Cited: 6
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Saghar Rabiei Poor, Miren Ettcheto, Amanda Cano, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 890-890
Open Access | Times Cited: 33
Actions and Consequences of Insulin in the Striatum
Jyoti C. Patel, Kenneth D. Carr, Margaret E. Rice
Biomolecules (2023) Vol. 13, Iss. 3, pp. 518-518
Open Access | Times Cited: 13
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
C. Duta, Corina Muscurel, Carmen Beatrice Dogaru, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1516-1516
Open Access
Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson’s Disease Rat Model
Prashant Delvadia, Vipin Dhote, Avinash Singh Mandloi, et al.
ACS Chemical Neuroscience (2025) Vol. 16, Iss. 5, pp. 818-825
Closed Access
Snapshot of disease continuum centered on Alzheimer's disease: Exploring modifiable risk factors
Ming Zheng
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 138, pp. 111316-111316
Closed Access
The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson's disease
Hangzhen Li, Fancai Zeng, Cancan Huang, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 30, Iss. 2
Open Access | Times Cited: 12
Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders
Swapnali Vasant Birajdar, Farhan Mazahir, Md Imtiyaz Alam, et al.
European Journal of Pharmacology (2023) Vol. 961, pp. 176117-176117
Closed Access | Times Cited: 12
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus
Houyu Zhao, Lin Zhuo, Yexiang Sun, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 17
The impact of diabetes mellitus on the development of psychiatric and neurological disorders
Olivia G. Kelly, Jillian Sullivan, Natalie Carris, et al.
Brain Disorders (2024) Vol. 14, pp. 100135-100135
Open Access | Times Cited: 3
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
Suzanne M. de la Monte
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S317-S343
Closed Access | Times Cited: 3
Diabetes medications as potential calorie restriction mimetics—a focus on the alpha-glucosidase inhibitor acarbose
Daniel L. Smith, Rachael M. Orlandella, David B. Allison, et al.
GeroScience (2020) Vol. 43, Iss. 3, pp. 1123-1133
Open Access | Times Cited: 26
Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson's disease
Gianni Pezzoli, Emanuele Cereda, Daniela Calandrella, et al.
Clinical Nutrition ESPEN (2024) Vol. 60, pp. 309-312
Closed Access | Times Cited: 2
The use of hypoglycemic drugs in Parkinson's disease: an updated meta-analysis of randomized controlled trials
Milene Vitória Sampaio Sobral, Victor Gonçalves Soares, João Lucas de Magalhães Leal Moreira, et al.
Parkinsonism & Related Disorders (2024), pp. 107210-107210
Closed Access | Times Cited: 2
Repurposing old molecules for new indications: Defining pillars of success from lessons in the past
Niti Mittal, Rakesh Mittal
European Journal of Pharmacology (2021) Vol. 912, pp. 174569-174569
Closed Access | Times Cited: 16
Onset and mortality of Parkinson’s disease in relation to type II diabetes
Gianni Pezzoli, Emanuele Cereda, Paolo Amami, et al.
Journal of Neurology (2022) Vol. 270, Iss. 3, pp. 1564-1572
Open Access | Times Cited: 10
Metformin Enhances Excitatory Synaptic Transmission onto Hippocampal CA1 Pyramidal Neurons
Wenbing Chen, Jiang Chen, Ziyang Liu, et al.
Brain Sciences (2020) Vol. 10, Iss. 10, pp. 706-706
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top